Takeda Launches ORZEYFUL in Japan and China
Takeda launched oveporexton, an OX2R agonist for narcolepsy type 1, giving physicians access to prescribe the therapy in both markets.
Related stories
South Korean Stocks Fall 3.5%, Down 16% This Month
South Korean shares closed down 3.5% Friday, bringing the month’s decline to 16%, as doubts about the global AI investment boom weighed on chipmakers.
M impact | EQUITY | Oct 30, 2026, 07:39 AM UTC
Ahold Delhaize to Acquire Tesco’s Czech and Slovak Operations
Ahold Delhaize will acquire Tesco’s operations in the Czech Republic and Slovakia.
M impact | EQUITY | Oct 30, 2026, 07:36 AM UTC
Varun Beverages Quarterly Profit Rises on Volume Growth
Packaging costs weighed on margins.
M impact | EQUITY | Oct 30, 2026, 07:35 AM UTC
Tesco Reports GBP2.9B Combined Sales in Czech Republic and Slovakia
M impact | EQUITY | Oct 30, 2026, 07:35 AM UTC
Panasonic Battery Unit Q2 Operating Profit Rises to 55.6 Billion Yen
Panasonic said operating profit at its energy unit rose from 1.2 billion yen a year earlier, citing higher sales of in-vehicle batteries and data centre energy storage systems. The
H impact | EQUITY | Oct 30, 2026, 07:35 AM UTC
Nikkei falls nearly 3% as technology shares retreat
The Nikkei fell nearly 3% as technology shares declined.
M impact | EQUITY | Oct 30, 2026, 07:34 AM UTC